Fadlo R. Khuri, MD, FACP

Professor, Hematology & Medical Oncology

Emory University School of Medicine


Dr. Fadlo Khuri maintains his appointment as Professor of the Department of Hematology and Medical Oncology at Emory University School of Medicine. He is the former Executive Associate Dean of Research and the former Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also served as Deputy Director for the Winship Cancer Institute of Emory University.

Dr. Khuri was also the Roberto C. Goizueta Distinguished Chair for Cancer Research. In his 13 years at Emory, he was instrumental in leading the development of some of the most important cancer-related programs in the state of Georgia and throughout the nation. He continues to serve as editor-in-chief of the journal, Cancer.

Dr. Khuri's clinical interests include thoracic and head and neck oncology. His research interests include the development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco-related cancers. His team is investigating the mechanism of action of signal transduction inhibitors in lung and aerodigestive tract cancers.

Dr. Khuri is an accomplished molecular oncologist who has conducted seminal research on oncolytic viral therapy. He developed molecular-targeted therapeutic approaches for lung and head and neck tumors that combine signal transduction inhibitors with chemotherapy, and he has led major chemoprevention efforts in lung and head and neck cancer.

Full Clinical Bio >>


Dr. Khuri's contributions in cancer research and patient care have been recognized by a number of institutional and national awards, including the prestigious Nagi Sahyoun Award in 2006 by the Middle East Medical Assembly for "his outstanding contributions to clinically relevant scientific research," election to the American Society of Clinical Investigation in 2007, and the Waun Ki Hong Award from MD Anderson for his "pioneering work on targeting signaling pathways in lung and aerodigestive cancers" in 2010.